Edition:
United States

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

1.34USD
15 Dec 2017
Change (% chg)

$-0.06 (-4.29%)
Prev Close
$1.40
Open
$1.42
Day's High
$1.43
Day's Low
$1.34
Volume
35,041
Avg. Vol
49,511
52-wk High
$15.50
52-wk Low
$1.28

Chart for

About

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC)... (more)
No analyst recommendations are available for .

Overall

Beta: -0.78
Market Cap(Mil.): $19.46
Shares Outstanding(Mil.): 14.52
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 198.20 16.04
EPS (TTM): -- -- --
ROI: -- -11.76 34.69
ROE: -- -36.72 15.46

BRIEF-Diffusion Pharma gets FDA protocol guidance for phase 3 trial with TSC

* Diffusion Pharmaceuticals receives final FDA protocol guidance for phase 3 clinical trial with TSC in patients newly diagnosed with inoperable glioblastoma multiforme

Oct 17 2017

Earnings vs. Estimates